Company news

Foghorn Therapeutics Inc. news in 2026

Foghorn Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

November 9, 2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November

November 3, 2026

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

October 1, 2026

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

August 6, 2026

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 5, 2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

May 12, 2026

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

May 7, 2026

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

April 21, 2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

April 9, 2026

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

March 11, 2026

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

February 23, 2026

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

February 3, 2026

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

January 13, 2026

2026 January Foghorn Investor Presentation (a105ae)

January 12, 2026

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

January 8, 2026

Decks in 2026